BenevolentAI

BenevolentAI is a clinical-stage AI-enabled drug discovery and development company headquartered in London, with research facilities in Cambridge and an office in New York. The company leverages its advanced AI platform, scientific expertise, and laboratory capabilities to create novel drug candidates, aiming for a higher probability of clinical success compared to traditional drug development methods. The Benevolent Platform supports a robust pipeline of over 20 drug programs, including both named and exploratory initiatives, and the company collaborates with major pharmaceutical firms and prominent research institutions.